US drug regulator blocks Regeneron’s blood cancer therapy
The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.
Drugs
Health
Pharma
Drugs
Health
Pharma
Johnson & Johnson’s blood cancer medicine cleared for bi-weekly use
HQ Team February 21, 2024: Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli. The regulatory.